Friday, 16 October 2026European Markets

QUESTERRE ENERGY Stock Was Up By 17.84% On Monday

Loading stream...

(VIANEWS) - The Market ended the session with QUESTERRE ENERGY (QEC.OL) rising 17.84% to kr2.18 on Monday while Oslo Børs Benchmark Index_GI rose 0.13% to kr1,442.35.

QUESTERRE ENERGY's last close was kr1.85, 30.97% below its 52-week high of kr2.68.

About QUESTERRE ENERGY

Questerre Energy Corporation, an energy technology and innovation company, acquires, explores, and develops non-conventional oil and gas projects in Canada. It produces tight oil, oil shale, shale oil, and shale gas. The company primarily holds 40,320 acres located in Kakwa, Alberta, including 25% working interest in 10,080 acres in Kakwa Central; 50% working interest in 4,480 acres in Kakwa North; 50% interest in 22,040 acres in Kakwa West; and 50% interest in 3,840 acres in Kakwa South. It also has 100% working interest in 11,316 acres located in Antler, Saskatchewan; and oil shale assets in Jordan. The company was formerly known as Westpro Equipment Ltd. and changed its name to Questerre Energy Corporation in December 2000. The company was incorporated in 1971 and is headquartered in Calgary, Canada.

Earnings Per Share

As for profitability, QUESTERRE ENERGY has a trailing twelve months EPS of kr-0.48.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -15.94%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, QUESTERRE ENERGY's stock is considered to be oversold (<=20).

More news about QUESTERRE ENERGY (QEC.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com